24-GBM-16-NL (EF-41): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune Concomitant with Maintenance Temozolomide and Placebo for the Tre

Grants and Contracts Details

StatusActive
Effective start/end date12/4/2412/4/26

Funding

  • Novocure GmbH: $2.00